Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
Could new cancer drugs restore immune responses against HIV?
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.
A genomic sequencing program revealed a genetic mutation that was able to be successfully treated with a checkpoint inhibitor.
While the team has found some interesting connections, there’s still a mountain of data to explore, say the study’s authors.
Ed Doelp lives with his wife, Dawn, in Smithville, New Jersey. Now in his 60s, he was diagnosed with kidney cancer in 2012.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.
An early study conducted among those with indolent lymphoma showed promising results.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.